エピジェネティックなスイッチは新しいがん治療の標的となる可能性(This epigenetic switch could be targeted by new cancer therapies)

ad

2026-03-11 ロックフェラー大学

ロックフェラー大学研究チームは、がん細胞増殖関与する新た制御機構発見した。研究では、DNA配列遺伝子発現調節する「ク・スイッチ」特定遺伝子活性切り替え、腫瘍形成進行影響すること明らかした。このスイッチ細胞遺伝子発現プログラム設定する役割持ち、がん細胞増殖生存有利状態変化する要因なる可能性ある。研究成果は、この機構標的する新しいがん治療法開発つながる可能性示し、精密医療分子標的治療発展寄与すると期待れる。

エピジェネティックなスイッチは新しいがん治療の標的となる可能性(This epigenetic switch could be targeted by new cancer therapies)
Violin plots showing changes in RNA expression (Credit: Allis lab)

<関連情報>

EZH2の保存されたN末端SANT1結合ドメイン(SBD)はPRC2の活性を制御する The conserved N-terminal SANT1-binding domain (SBD) of EZH2 regulates PRC2 activity

Agata L. Patriotis,,Douglas W. Barrows,Yadira Soto-Feliciano,,Laiba F. Khan,Marylene Leboeuf,Dylan M. Marchione,Matthew R. Marunde,Michael-Christopher Keogh,Thomas S. Carroll,Benjamin A. Garcia,,Alexey A. Soshnev, andC. David Allis
Genes & Development  Published:February 9, 2026
DOI:10.1101/gad.353070.125

Abstract

Polycomb group proteins maintain gene expression patterns established during early development, with Polycomb repressive complex 2 (PRC2) methyltransferase being a key regulator of cell differentiation, identity, and plasticity. Consequently, extensive somatic mutations in PRC2, including gain or loss of function (GOF or LOF), are observed in human cancers. The regulation of chromatin structure by PRC2 is critically dependent on its enhancer of zeste homolog 2 (EZH2) subunit, which catalyzes the methylation of histone H3 lysine 27 (H3K27). Recent structural studies of PRC2 revealed extensive conformational changes in the noncatalytic EZH2 N-terminal SANT1-binding domain (SBD) during PRC2 activation, though the functional significance remains unclear. Here, we investigated how the SBD regulates PRC2 function. The domain is highly conserved in metazoans and dispensable for PRC2 assembly and chromatin localization yet is required for genome-wide histone H3K27 methylation. Furthermore, we show that an intact SBD is necessary for the proliferation of EZH2-addicted lymphomas, and its deletion in the presence of EZH2 GOF mutations inhibits cancer cell growth. These observations provide new insights into the regulation of PRC2 activity in normal development and malignancy.

細胞遺伝子工学
ad
ad
Follow
ad
タイトルとURLをコピーしました